Skip to main content
. 2022 Dec 1;12(12):e1104. doi: 10.1002/ctm2.1104

TABLE 3.

Effects of suggestive genetic variations on the pharmacodynamics of dabigatran

Gene SNP Genotypes a Peak PD levels Trough PD levels
GENO b FIIa (ng/ml) p‐Value FAPTT (s) p‐Value FPT (s) p‐Value GENO GIIa (ng/ml) p‐Value GAPTT (s) p‐Value GPT (s) p‐Value
SNX7 rs9433747 A1A1 0/28/127 / 1.70 × 10−7 / 1.88 × 10−3 / 6.41 × 10−5 0/27/124 / 0.025 / .582 / .828
A1A2 228.26 ± 161.58 54.12 ± 13.62 15.14 ± 2.48 90.39 ± 70.74 40.50 ± 8.62 12.80 ± 1.30
A2A2 133.62 ± 111.91 47.00 ± 13.37 13.86 ± 3.76 63.31 ± 56.42 39.35 ± 10.11 13.92 ± 6.67
BRD4 rs11669901 A1A1 1/18/136 287.67 2.90 × 10−6 51.8 .096 13.60 .172 1/17/133 131.07 0.015 35.0 .665 11.10 .660
A1A2 219.50 ± 172.25 52.03 ± 10.67 14.36 ± 2.25 98.71 ± 87.31 41.55 ± 8.01 12.83 ± 1.57
A2A2 140.56 ± 117.38 47.77 ± 14.01 14.06 ± 3.75 63.78 ± 54.43 39.33 ± 10.09 13.86 ± 6.45
FLCN rs3744124 A1A1 6/54/95 288.71 ± 193.56 4.77 × 10−6 65.37 ± 21.22 6.05 × 10−3 21.15 ± 12.97 .169 6/51/94 135.92 ± 104.60 6.40E‐03 52.30 ± 13.05 .064 17.73 ± 9.76 .729
A1A2 150.23 ± 135.44 47.15 ± 13.86 13.81 ± 2.43 67.13 ± 60.37 37.45 ± 9.39 13.42 ± 5.71
A2A2 142.19 ± 111.94 47.86 ± 12.20 13.80 ± 1.97 64.39 ± 53.15 39.88 ± 9.22 13.63 ± 5.89
UBAP1 rs1556439 A1A1 1/15/139 455.10 .117 66.30 .054 16.70 .063 1/14/136 263.48 6.69E‐06 45.80 .011 13.00 .083
A1A2 182.90 ± 109.48 53.83 ± 14.08 14.79 ± 2.06 117.20 ± 88.94 46.56 ± 11.97 17.54 ± 11.03
A2A2 144.97 ± 126.69 47.56 ± 13.47 13.99 ± 3.73 61.67 ± 51.29 38.79 ± 9.35 13.33 ± 5.19
IGLV3‐12 rs2073451 A1A1 30/74/51 120.01 ± 94.94 .021 43.33 ± 11.40 8.50 × 10−6 13.42 ± 1.91 1.61 × 10−4 29/75/47 63.12 ± 47.87 0.638 37.56 ± 8.39 .120 12.78 ± 1.82 .904
A1A2 151.86 ± 134.17 47.54 ± 13.55 14.10 ± 4.64 68.02 ± 65.70 39.37 ± 10.16 13.54 ± 5.30
A2A2 166.76 ± 131.18 52.29 ± 13.98 14.47 ± 2.37 71.48 ± 57.36 41.06 ± 10.00 14.60 ± 8.42
LRRC8E rs3745382 A1A1 4/29/122 213.08 ± 107.13 9.22 × 10−3 50.10 ± 14.00 .067 13.70 ± 2.05 .282 3/28/120 184.95 ± 105.36 1.74E‐03 52.07 ± 19.68 8.41 × 10−6 16.90 ± 5.43 .143
A1A2 172.76 ± 143.83 54.62 ± 15.02 15.33 ± 6.85 78.56 ± 69.50 45.13 ± 10.62 15.17 ± 8.64
A2A2 143.35 ± 122.89 46.72 ± 12.88 13.80 ± 2.17 62.81 ± 52.45 37.94 ± 8.53 13.30 ± 5.25
PTPLAD1 rs11539008 A1A1 0/22/133 / .209 / 3.09 × 10−3 / .012 0/21/130 / 1.41E‐03 / 9.69 × 10−6 / .024
A1A2 162.47 ± 135.75 54.38 ± 16.79 14.80 ± 2.81 105.75 ± 92.08 47.90 ± 38.20 17.63 ± 11.98
A2A2 148.56 ± 126.02 47.28 ± 12.83 13.97 ± 3.70 62.08 ± 50.65 10.65 ± 9.04 13.09 ± 4.12
ZNF230 rs12753 A1A1 11/52/92 144.02 ± 176.03 1.86 × 10−4 48.35 ± 19.92 2.99 × 10−4 14.84 ± 3.28 1.97 × 10−6 10/49/92 50.26 ± 65.69 0.414 37.10 ± 9.68 .820 12.75 ± 0.97 .760
A1A2 156.90 ± 126.10 50.95 ± 13.29 14.23 ± 2.12 82.24 ± 73.63 40.16 ± 9.34 14.38 ± 8.21
A2A2 147.77 ± 121.26 46.78 ± 12.73 13.92 ± 4.23 62.60 ± 49.07 39.50 ± 10.12 13.48 ± 4.95
ANP32A rs12904108 A1A1 5/41/109 103.61 ± 108.62 .841 47.04 ± 12.89 .391 13.20 ± 1.58 .277 5/40/106 56.31 ± 27.70 0.477 42.04 ± 9.95 .143 26.82 ± 18.10 7.13 × 10−7
A1A2 162.36 ± 137.36 49.73 ± 10.94 14.25 ± 2.23 77.40 ± 65.59 41.22 ± 8.57 14.15 ± 6.91
A2A2 148.36 ± 123.95 47.80 ± 14.59 14.07 ± 4.05 65.23 ± 58.69 38.81 ± 10.23 12.94 ± 3.25
SLC25A28 rs12252561 A1A1 9/44/102 173.09 ± 85.29 .796 54.33 ± 10.10 .291 14.34 ± 1.47 .219 8/43/100 105.80 ± 71.81 0.226 47.69 ± 10.39 .0499 23.50 ± 15.12 7.81 × 10−7
A1A2 129.74 ± 101.74 48.70 ± 10.35 13.91 ± 1.75 69.65 ± 73.56 40.56 ± 8.22 13.92 ± 6.59
A2A2 157.56 ± 139.00 47.57 ± 15.03 14.14 ± 4.26 64.50 ± 50.93 38.47 ± 10.13 12.85 ± 3.26
ABCC2 rs2273697 A1A1 3/21/131 209.74 ± 74.86 .598 51.83 ± 11.05 .441 14.20 ± 1.36 .426 2/21/128 98.32 ± 10.57 0.052 44.70 ± 6.60 .286 32.10 ± 19.20 3.10 × 10−6
A1A2 161.40 ± 104.82 49.48 ± 9.88 13.84 ± 1.87 95.65 ± 96.79 42.03 ± 11.47 17.13 ± 11.46
A2A2 147.55 ± 131.37 48.01 ± 14.24 14.13 ± 3.84 63.17± 50.64 39.07 ± 9.54 12.88 ± 2.92
ABCC2 rs4148395 A1A1 3/21/131 209.74 ± 74.86 .598 51.83 ± 11.05 .441 14.20 ± 1.36 .426 2/21/128 98.32 ± 10.57 0.052 44.70 ± 6.60 .286 32.10 ± 19.20 3.10 × 10−6
A1A2 161.40 ± 104.82 49.48 ± 9.88 13.84 ± 1.87 95.65 ± 96.79 42.03 ± 11.47 17.13 ± 11.46
A2A2 147.55 ± 131.37 48.01 ± 14.24 14.13 ± 3.84 63.17 ± 50.64 39.07 ± 9.54 12.88 ± 2.92
MYBPC1 rs11110942 A1A1 7/61/87 112.94 ± 83.09 .739 50.53 ± 6.80 .708 13.77 ± 1.03 .776 7/59/85 67.07 ± 49.26 0.239 44.83 ± 9.39 .292 24.00 ± 17.42 4.46 × 10−6
A1A2 146.66 ± 107.43 47.03 ± 10.69 13.75 ± 1.90 75.23 ± 72.71 39.38 ± 9.01 13.85 ± 5.41
A2A2 156.34 ± 141.97 48.99 ± 15.75 14.35 ± 4.51 63.34 ± 49.96 39.24 ± 10.35 12.79 ± 3.31
MYBPC1 rs3751246 A1A1 7/62/86 112.94 ± 83.09 .739 50.53 ± 6.80 .708 13.77 ± 1.03 .776 7/60/84 67.07 ± 49.26 0.270 44.83 ± 9.39 .240 24.00 ± 17.42 4.46 × 10−6
A1A2 147.79 ± 106.92 47.22 ± 10.71 13.79 ± 1.90 75.13 ± 72.11 39.59 ± 9.08 13.87 ± 5.37
A2A2 155.65 ± 142.63 48.87 ± 15.80 14.33 ± 4.53 63.26 ± 50.26 39.08 ± 10.31 12.76 ± 3.32
MYBPC1 rs11110952 A1A1 7/63/85 112.94 ± 83.09 .739 50.53 ± 6.80 .708 13.77 ± 1.03 .776 7/60/84 67.07 ± 49.26 0.270 44.83 ± 9.39 .240 24.00 ± 17.42 4.46 × 10−6
A1A2 147.07 ± 106.22 47.35 ± 10.68 13.81 ± 1.89 75.13 ± 72.11 39.59 ± 9.08 13.87 ± 5.37
A2A2 156.26 ± 143.35 48.79 ± 15.88 14.32 ± 4.56 63.26 ± 50.26 39.08 ± 10.31 12.76 ± 3.32
CEP170B rs60001925 A1A1 3/34/118 109.85 ± 14.90 .852 58.70 ± 5.77 .443 14.43 ± 1.81 .400 3/30/118 32.15 ± 21.05 0.481 44.93 ± 2.95 .113 24.67 ± 15.45 5.53 × 10−6
A1A2 147.58 ± 132.20 49.34 ± 12.49 14.24 ± 2.09 71.14 ± 55.42 41.79 ± 10.38 15.79 ± 10.33
A2A2 152.50 ± 127.65 47.72 ± 14.03 14.04 ± 3.96 68.31 ± 61.65 38.85 ± 9.72 12.92 ± 3.08
GYPA rs145195209 A1A1 2/21/132 110.87 ± 8.19 .280 71.35 ± 17.55 .604 15.70 ± 3.30 .818 1/22/128 60.08 0.601 46.50 .920 46.50 9.24 × 10−6
A1A2 148.31 ± 163.25 44.61 ± 11.77 13.60 ± 1.94 63.45 ± 75.96 39.28 ± 9.41 14.66 ± 8.22
A2A2 151.59 ± 121.54 48.52 ± 13.53 14.14 ± 3.79 69.03 ± 57.18 39.54 ± 9.97 13.30 ± 4.84

Abbreviations: A1, minor allele; A2, non‐minor allele; GENO, number of each genotype (A1A1/A1A2/A2A2); SNP, single‐nucleotide polymorphism.

a

SNX7 SNP rs9433747: A1 = G, A2 = A; BRD4 SNP rs11669901: A1 = A, A2 = G; FLCN SNP rs3744124: A1 = T, A2 = C; UBAP1 SNP rs1556439: A1 = T, A2 = C; IGLV3‐12 SNP rs2073451: A1 = G, A2 = A; LRRC8E SNP rs3745382: A1 = A, A2 = G; PTPLAD1 SNP rs11539008: A1 = A, A2 = G; ZNF230 SNP rs12753: A1 = A, A2 = C; ANP32A SNP rs12904108: A1 = T, A2 = A; SLC25A28 SNP rs12252561: A1 = C, A2 = G; ABCC2 SNP rs2273697: A1 = A, A2 = G; ABCC2 SNP rs4148395: A1 = A, A2 = G; MYBPC1 SNP rs11110942: A1 = G, A2 = C; MYBPC1 SNP rs3751246: A1 = T, A2 = C; MYBPC1 SNP rs11110952: A1 = C, A2 = T; CEP170B SNP rs60001925: A1 = C, A2 = CGCAGGA; GYPA SNP rs145195209: A1 = A, A2 = AT.

b

As the number of peak anti‐FIIa activity was 156 and the number of peak APTT and PT was 155, the genotype of extra one that had only peak anti‐FIIa activity was: SNX7 SNP rs9433747: A2A2; BRD4 SNP rs11669901: A2A2; FLCN SNP rs3744124: A2A2; UBAP1 SNP rs1556439: A2A2; IGLV3‐12 SNP rs2073451: A1A2; LRRC8E SNP rs3745382: A2A2; PTPLAD1 SNP rs11539008: A1A2; ZNF230 SNP rs12753: A1A2; ANP32A SNP rs12904108: A2A2; SLC25A28 SNP rs12252561: A2A2; ABCC2 SNP rs2273697: A2A2; ABCC2 SNP rs4148395: A2A2; MYBPC1 SNP rs11110942: A2A2; MYBPC1 SNP rs3751246: A2A2; MYBPC1 SNP rs11110952: A2A2; CEP170B SNP rs60001925: A2A2; GYPA SNP rs145195209: A1A2.